Novozymes acquires enzyme business from Canadian Iogen Corporation
date:Feb 04, 2013
h in 2013 of around 0.5 percentage point depending on when the acquisition is closed. The acquisition is expected to have a slightly negative impact on EBIT and EBIT margin in 2013, but outlook for EBIT growth and EBIT margin remains unchanged. The outlook for ROIC for 2013 is being changed from ~20% to 19-20% as a result of the additional capital invested. Novozymes' outlook for free cash flow excludes acquisitions and remains unchanged for 2013. Outlook assumes rates for the companys key curre
3/4 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
07/11 05:51